Resources

Publications

 

 

Show All

December 2012

Yu X , Seitz S, Pointon T, Bowlin JL, Cohrs RJ, Jonjić S, Haas J, Wellish M, and Gilden D

Varicella Zoster Virus Infection of Highly Pure Terminally Differentiated Human Neurons

J Neurovirol 19(1):75-81

Publication Date: December 12, 2012

Product Type: iCell GABANeurons

Summary:

iCell Neurons were used to develop a novel in vitro model of varicella zoster virus (VZV) infection. Infection of iCell Neurons with VZV yields a non-productive infection with detectable expression of immediate-early, early, and late viral genes, but no evidence of apoptosis, which together will enable molecular analysis of VZV-neuron interactions and mechanisms of VZV reactivation.

Impact:

iCell Neurons provided a biologically relevant human cell model to study mechanisms of VZV infection, which was previously not possible using primary neuronal cells due to limitations in cell functionality and purity.

Xu X, Lei Y, Luo J, Wang J, Zhang S, Yang XJ, Sun M, Nuwaysir E, Fan G, Zhao J, Lei L, and Zhong Z

Prevention of ß-amyloid Induced Toxicity in Human iPS Cell-derived Neurons by Inhibition of Cyclin-dependent Kinases and Associated Cell Cycle Events

Stem Cell Res 10(2):213-27

Publication Date: December 7, 2012

Product Type: iCell GABANeurons

Summary:

iCell Neurons were used to develop a novel, robust, and sensitive Aß toxicity-mediated model of Alzheimer’s disease, which was subsequently used in a screen of several hundred compounds from a proprietary GlaxoSmithKline compound library. Nineteen hits were identified, and one hit, a Cdk2 inhibitor, was selected for a follow up study using iCell Neurons to confirm the mechanism of action.

Impact:

iCell Neurons were successfully used to model Alzheimer’s disease and employed in a high-throughput small molecule screen for modulators of the disease phenotype. This is the first known example of iPS cell-derived neurons used in an Aß toxicity screen and demonstrates the use of iCell Neurons for disease modeling and drug screening for neurodegenerative disease.